Bruce C. Cozadd is the CEO and Chairman of Jazz Pharmaceuticals, Inc., which he co-founded in 2003. He stepped into the CEO role in April 2009 and has been steering the company ever since. Cozadd's leadership is marked by his...

Bruce C. Cozadd is the CEO and Chairman of Jazz Pharmaceuticals, Inc., which he co-founded in 2003. He stepped into the CEO role in April 2009 and has been steering the company ever since. Cozadd's leadership is marked by his deep involvement in the pharmaceutical industry, particularly in developing and promoting impactful treatments. One interesting fact is that his compensation package saw a significant jump in 2011, largely driven by a performance bonus and the vesting of stock options linked to a merger with Azur Pharma. Throughout his career, he has managed impressive stock valuation fluctuations, peaking around $57 million in 2021. His tenure has not only focused on growth but has also led to noteworthy corporate acquisitions, broadening Jazz Pharmaceuticals' portfolio. Cozadd's strategic decisions directly contribute to the company's market presence and future direction. Currently, at age 60, he continues to spearhead innovation and operational excellence at Jazz Pharmaceuticals, a role he has embraced for over a decade.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Jazz Pharmaceuticals CEOs

J

Bruce C. Cozadd

Founder and CEO of Jazz Pharmaceuticals

Education

Not specified

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

January 1, 1963 - 62 years ago

CEO of Jazz Pharmaceuticals for

16 years 2 months (Apr 2009 - Present)

Previous Experience

Co-founded Jazz Pharmaceuticals, Inc. in 2003; served as Chief Executive Officer since April 2009

Rivals

Competitors/colleagues of Bruce C. Cozadd

A

Herriot Tabuteau, M.D.

Founder and CEO of Axsome Therapeutics

2023 Compensation

Stock

$0.00

Salary

$750.00K

Bonus

$562.50K

Other

$82.96K

Total Holdings

$874.56M

Holdings

See how much did Bruce C. Cozadd make over time.

Bruce C. Cozadd holds a significant stake in Jazz Pharmaceuticals, with his holdings showing notable fluctuations over the years. In 2019, his stock value was approximately $40.58 million, and it peaked at about $57.29 million in June 2021. His wealth...

Bruce C. Cozadd holds a significant stake in Jazz Pharmaceuticals, with his holdings showing notable fluctuations over the years. In 2019, his stock value was approximately $40.58 million, and it peaked at about $57.29 million in June 2021. His wealth as an insider has been tied closely to the company's stock performance, reflecting his commitment to Jazz. As of late 2023, his holdings are valued around $46 million. This trajectory indicates that Cozadd has navigated challenges and opportunities in the stock market, aligning his interests with those of shareholders. His ability to maintain such a large stake demonstrates both confidence in Jazz's future and a strong incentive to drive the company's growth further.

Mar 18, 2025

J

shares

JAZZ @ $139.51

Total Stock Sold

$67.72M

JAZZ

$67.72M

513,674 JAZZ shares

CERS

$6.11K

1,409 CERS shares

What if they kept their stock?

If Bruce C. Cozadd didn't sell their stock, today they would have:
Extra JAZZ513,674 shares worth $62.61M and CERS1,409 shares worth $8.24K.
This is -7.54% and $5.11M less than what they got when they sold the stock.

Charitable Transactions

JAZZ

10,422 shares

JAZZ

Recent Charitable Transactions

JAZZ

10,422 shares

JAZZ

Feb 27, 2014

Charity

Insider Trading

See recent insider trades of Bruce C. Cozadd.

JAZZ

$937.63K

JAZZ at $144.25/share

Feb 27, 2025

Sale

JAZZ

30,814 shares

JAZZ

Feb 27, 2025

Received

JAZZ

$183.47K

JAZZ at $122.31/share

Feb 3, 2025

Sale

JAZZ

29,559 shares

JAZZ

Jan 17, 2025

Received

JAZZ

$185.15K

JAZZ at $123.43/share

Jan 2, 2025

Sale

JAZZ

$242.34K

JAZZ at $121.17/share

Dec 2, 2024

Sale

JAZZ

$110.84K

JAZZ at $110.84/share

Nov 1, 2024

Sale

JAZZ

50,187 shares

JAZZ

Mar 1, 2024

Received

JAZZ

26,545 shares

JAZZ

Jan 17, 2024

Received

JAZZ

42,388 shares

JAZZ

Mar 3, 2023

Received

Compensation History

See how much did Bruce C. Cozadd make over time.

In terms of compensation, Bruce C. Cozadd’s financial rewards serve as a reflection of his impact at Jazz Pharmaceuticals. In 2011, he received a total compensation of about $3.9 million, a mix of salary, bonuses, and stock options due to a significant merger. His base salary was $563,173, with a $552,000 performance bonus and valued vested stock options of roughly $3 million, driven by company growth and operational success at that time. Over the years, his compensation has fluctuated, but it has tailored to align with the performance metrics of Jazz Pharmaceuticals, ensuring he is rewarded for achievements that support the company’s goals. As of the latest data, Cozadd's overall annual compensation has varied, reflecting both the company’s health and his individual contributions to executive performance goals that resonate with shareholders.

Year

2011

Total Compensation

$4.19M

Salary

$563.17K

Board Justification

The compensation philosophy is designed to align executive compensation with company performance, peer benchmarking, and retention strategies, ensuring competitive pay to attract and retain top talent.

Bonus

$552.00K

Board Justification

The bonus awarded under the performance bonus plan for the year 2011, based on company performance metrics and individual contributions.

Other

$1.71K

Board Justification

Represents group term life insurance premiums paid by Jazz Pharmaceuticals, Inc.

Restricted Stock

$3.08M(214.8K NSOs)

Board Justification

The stock options that vested in 2011 due to the acceleration of vesting in connection with the merger with Azur Pharma.

Performance Metrics

The performance metrics included achieving budgeted net sales, revenue growth, and adjusted net income targets.

Other Jazz Pharmaceuticals CEOs

Here are other CEOs of Jazz Pharmaceuticals

Samuel R. Saks

Ex-CEO of Jazz Pharmaceuticals

January 2008 - March 2011